Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study

Emergence of new molecules acting directly on the hepatitic C virus (HCV) has improved treatment outcomes. However, there is a risk of selecting viral escape mutants, so a new combination is needed using different inhibitors that target different steps of the HCV infectious cycle. Novel single table...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiha, Gamal, Soliman, Reham, Elbasiony, Mohamed, Darwish, Noureldien H. E., Mousa, Shaker A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753069/
https://www.ncbi.nlm.nih.gov/pubmed/31537880
http://dx.doi.org/10.1038/s41598-019-49973-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753069/
https://www.ncbi.nlm.nih.gov/pubmed/31537880
http://dx.doi.org/10.1038/s41598-019-49973-6

Ejemplares similares